Posts by Constance

21 hours ago

Egle Therapeutics to Present Clinical Data at the Upcoming European Academy of Dermatology and Venereology (EADV) Congress in Vienna

Egle to share clinical data on EGL-003, the company’s most advanced Treg-selective IL-2 agonist for atopic dermatitis Paris, France, (September 15, 2026) – Egle Therapeutics (“Egle”), a clinical-stage biotechnology company…

7 months ago

Egle Therapeutics and Consortium Partners Awarded €8 Million Grant from Horizon Europe to Advance Clinical Development of EGL-001 in Neoadjuvant Head and Neck Cancer

Paris, France, March 2, 2026 – Egle Therapeutics SAS (Egle), a clinical-stage biotechnology company pioneering precision medicines that modulate regulatory T cells (Tregs) to rebalance immune function in patients with…

8 months ago

Egle Therapeutics Appoints John Celebi as Chief Executive Officer

Paris, France, Jan. 7, 2026 – Egle Therapeutics SAS (Egle), a clinical-stage biotechnology company pioneering precision medicines that modulate regulatory T cells (Tregs) to rebalance immune function in patients with…

10 months ago

Egle Therapeutics Initiates Phase 1 Healthy Volunteer Study of EGL-003, a Next Generation Treg IL-2 Agonist for Atopic Dermatitis

Paris, France, Dec. 1, 2025 – Egle Therapeutics SAS (Egle), a clinical-stage biotechnology company developing precision medicines that modulate regulatory T cells (Tregs) to restore immune balance, today announced dosing…

1 year ago

International Congress of Immunology – IUIS 2025

Dates : 17 – 22 August 2025 Location : Vienna, Austria Several representatives from our laboratory will have the pleasure of participating in the 19th International Congress of Immunology, organized…

1 year ago

Egle Therapeutics to Present New Preclinical Data EGL-003, a Novel IL-2 Mutein for Selective Expansion of Tregs to Restore Immune Balance with Best-in-class Potential, at EULAR 2025 Congress

Paris, France, June 10th 2025 – Egle Therapeutics, a clinical-stage biotechnology company developing therapies targeting regulatory T cells (Tregs) for immuno-oncology and autoimmune diseases, today announced a poster presentation at…

1 year ago

Egle Therapeutics to Present Clinical Trial Progress Poster on Phase I/II EGL-121 Study for EGL-001 at 2025 ASCO Annual Meeting

Egle Therapeutics, a clinical-stage biotechnology company developing therapies targeting regulatory T cells (Tregs) for immuno-oncology and autoimmune diseases, today announced a poster presentation at the upcoming 2025 American Society of…

1 year ago

Egle Therapeutics to highlight novel preclinical findings for regulatory T cells targeting programs EGL-001 and EGL-002 with poster presentations at the 2025 AACR Annual Meeting

Egle Therapeutics, a clinical-stage biotechnology company developing therapies targeting regulatory T cells (Tregs) for immuno-oncology and autoimmune diseases, will present two posters at the American Association for Cancer Research Annual…

1 year ago

American Society of Clinical Oncology – Annual Congress 2025

Dates : 30 May – 3 June 2025 Location : Chicago, Illinois Several representatives from our laboratory will have the pleasure of participating in the ASCO 2025 congress. Learn more…